Investors
Stock Quote
ICCC Stock Price
Current: $7.08
Data provided by Yahoo Finance. Prices may be delayed. Not financial advice.
Press Releases
Recent News | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC Filings
SEC Filings
Annual Report and Proxy
Corporate
Governance
ICCC Code of Conduct
Charter and Powers of the Audit Committee
Nominating Committee Charter
Management & Directors
Recent News
- 04-08-26 – ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
- 03-18-26 ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
- 03-04-26 ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
- 02-18-26 ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
- 01-08-26 ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
- 01-07-26 ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
- 12-24-25 – ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
- 11-13-25 – ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
- 11-06-25 – ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
- 11-04-25 – ImmuCell Announces Onboarding of New CEO and Related Management Changes
- 10-07-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
- 09-29-25 – ImmuCell Announces Selection of its Next President and CEO
- 08-14-25 – ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025
- 08-12-25 – ImmuCell Announces Bank Debt Refinancing
- 08-07-25 – ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
- 07-09-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
- 06-25-25 – ImmuCell Embarks on CEO Succession Planning Process
- 06-05-25 – ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
- 05-14-25 – ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
- 05-12-25 – ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
- 04-08-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
- 04-07-25 – ImmuCell Hires Chief Financial Officer
- 04-02-25 – ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
- 02-25-25 – ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
- 02-20-25 – ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
- 01-16-25 – ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses
- 01-09-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
Company Contact
Olivier te Boekhorst
President & CEO
investor.relations@immucell.com
Investor Contact
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700